The pharmaceutical cartridge market size is expected to grow from USD 1.86 billion in 2025 to USD 2.01 billion in 2026 and is forecast to reach USD 2.92 billion by 2031 at 7.80% CAGR over 2026-2031. This report is Segmented by Material (Glass [Type I and More], Engineering Plastics [COP/COC and More] and More), Delivery Device Compatibility (Reusable Pen Injectors, Autoinjectors and More), Capacity (< 3ml, 3ml-5ml, and More), Therapeutic Area (Ophthalmology and More), End User (Pharmaceutical Companies, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).
Pharmaceutical cartridge industry players invest in polymer lines that match glass output speeds, but glass suppliers reply with strengthened borosilicate such as SCHOTT EVERIC to cut cosmetic rejects. Oncology pipelines that require cryogenic storage lean toward polymer because its seal integrity outperforms glass at low temperatures. Sustainability debates add tension; polymers allow energy-lite molding, while glass touts proven recyclability. Competition will intensify as both camps market advanced coatings and siliconization upgrades to capture share within the pharmaceutical cartridge market.
Reusable pen injectors secured 43.55% of pharmaceutical cartridge market size in 2025, entrenched by decades of insulin therapy familiarity. Yet wearable on-body pumps are forecast to grow 10.98% CAGR through 2031 because they house 5-10 mL cartridges that deliver weekly GLP-1 or oncology biologics at home. BD Libertas wearable injectors proved subcutaneous delivery for agents up to 50 cP, confirming technical readiness.
Device makers now forge multi-supplier networks ensuring glass and elastomer fit across platforms, as Ypsomed coordinates more than 15 partners to secure global inventory. Gas-driven drivers and AI-monitored actuation force replace traditional springs to handle viscous drugs safely. Autoinjectors targeting 5.5 mL volumes arrive from Aktiv Medical Systems, pointing to higher-dose standards. These changes expand choice and lift the overall pharmaceutical cartridge market.
Europe follows closely owing to Annex 1 sterility reforms that push RTU adoption. Stevanato Group’s new Cisterna di Latina facility adds regional capacity for EZ-fill cartridges, aligning with the EU Critical Medicines Act that seeks supply-security via local output. Joint clinical-assessment rules and the forthcoming Health Technology Assessment Regulation unify demand, favouring suppliers with proven conformity across multiple markets.
Asia Pacific is forecast to grow 9.84% CAGR through 2031, the fastest worldwide. India’s Kapoor Glass exports 90% of its cartridge output to Western clients, underpinning the region’s cost-efficient manufacturing base. Regulatory harmonization through the Asia Partnership Conference of Pharmaceutical Associations sparks smoother cross-border approvals. Countries like South Korea and Singapore nurture biotech hubs, while China’s expanding biologics sector heightens need for high-quality containment. Collectively these initiatives cement Asia Pacific as a pivotal growth engine for the pharmaceutical cartridge market.
Global Pharmaceutical Cartridges Market Trends and Insights
Rising Demand for Self-Injection Pen and Wearable Injector Formats
Pen injectors and wearable pumps now anchor patient-centred treatment, letting individuals administer chronic therapies without clinic visits. Ypsomed sold over 12 million reusable pens and 1.7 billion prefilled pens in 2024, underscoring adoption scale. With roughly 500 million people living with type 2 diabetes and 1 billion affected by obesity, user-friendly devices that support frequent dosing have become essential. Clinical work shows subcutaneous injections up to 10 mL win 79% patient acceptance and pain returns to baseline within 30 minutes, so expanding cartridge volumes meets consumer comfort thresholds.Connected pens now log dosing data for adherence monitoring, turning delivery hardware into real-world evidence tools that strengthen pharma value propositions. The trend adds steady volume to the pharmaceutical cartridge market as home therapy shifts from exception to norm.Shift of GLP-1 Obesity and High-Viscosity Biologics to Cartridge Delivery
GLP-1 receptor agonists have become the fastest-growing pharmaceutical class and their migration from diabetes into obesity care drives new cartridge orders. West Pharmaceutical Services secured multiyear elastomer deals chiefly aimed at this vertical, with self-injection products already forming 73% of its proprietary segment sales. To handle formulations thicker than 15 cP, BD partnered with Ypsomed to pair Neopak XtraFlow glass syringes with autoinjectors, ensuring smooth subcutaneous delivery. Patent reviews show 57% of GLP-1 filings address delivery mechanisms rather than molecules, revealing competitive moats that could slow generic erosion while keeping cartridge demand high. Reloadable autoinjectors are surfacing as greener, lower-cost alternatives, but they still rely on rugged cartridges engineered for multiple actuations. These developments are injecting urgency into capacity build-outs across the pharmaceutical cartridge market.Complex Multi-Step Manufacturing and Stringent cGMP Validation
Cartridge fabrication requires precision tolerances for break-loose force, glide force, and plunger travel. USP < 382> now mandates container-closure system testing rather than individual component checks, adding fresh validation layers. Development cycles can lengthen 12-18 months as each variable undergoes statistical validation. AI tools add transparency demands because regulators want algorithm logic alongside performance metrics. High-grade cleanrooms, barrier isolators, and validated depyrogenation ovens raise capital thresholds, deterring new entrants and slowing capacity additions within the pharmaceutical cartridge market.Other drivers and restraints analyzed in the detailed report include:
- Emergence of Large-Volume Wearable On-Body Injector Cartridges (≥ 10 mL)
- EU MDR Annex 1 Sterility Rules Spurring RTU Cartridge Adoption
- Substitution Risk from Pre-Filled Syringes in ≤ 3 mL Range
Segment Analysis
Glass held 72.88% of overall pharmaceutical cartridge market share in 2025, reflecting decades of regulatory confidence and its inert, transparent nature. The segment benefits from broad line compatibility and ample legacy tooling across fill-finish sites. Engineering plastics, notably COC and COP, are rising at a 11.71% CAGR because they resist breakage and tolerate high-pH biology, advantageous for novel oncology agents. Regulatory endorsement arrived when TOPAS Advanced Polymers secured the first USP 661.1 compliance for cyclic olefins.Pharmaceutical cartridge industry players invest in polymer lines that match glass output speeds, but glass suppliers reply with strengthened borosilicate such as SCHOTT EVERIC to cut cosmetic rejects. Oncology pipelines that require cryogenic storage lean toward polymer because its seal integrity outperforms glass at low temperatures. Sustainability debates add tension; polymers allow energy-lite molding, while glass touts proven recyclability. Competition will intensify as both camps market advanced coatings and siliconization upgrades to capture share within the pharmaceutical cartridge market.
Reusable pen injectors secured 43.55% of pharmaceutical cartridge market size in 2025, entrenched by decades of insulin therapy familiarity. Yet wearable on-body pumps are forecast to grow 10.98% CAGR through 2031 because they house 5-10 mL cartridges that deliver weekly GLP-1 or oncology biologics at home. BD Libertas wearable injectors proved subcutaneous delivery for agents up to 50 cP, confirming technical readiness.
Device makers now forge multi-supplier networks ensuring glass and elastomer fit across platforms, as Ypsomed coordinates more than 15 partners to secure global inventory. Gas-driven drivers and AI-monitored actuation force replace traditional springs to handle viscous drugs safely. Autoinjectors targeting 5.5 mL volumes arrive from Aktiv Medical Systems, pointing to higher-dose standards. These changes expand choice and lift the overall pharmaceutical cartridge market.
Complete Report Scope:
- By Material
- Glass
- Type I (Borosilicate)
- Type II (Soda-lime treated)
- Type III (Soda-lime)
- Engineering Plastics
- COP/COC (Cyclic Olefin)
- PETG/Other Polymers
- Elastomers & Rubber Components
- Glass
- By Delivery-Device Compatibility
- Reusable pen injectors
- Disposable pen injectors
- Wearable on-body pumps
- Dental local-anaesthesia syringes
- Autoinjectors
- By Capacity (mL)
- < 3
- 3 - 5
- 5 - 10
- > 10 (large-volume)
- By Therapeutic Area
- Ophthalmology
- Respiratory
- Neurology
- Oncology
- Immunology (incl. mAbs)
- Cardiology
- Diabetes (insulins, GLP-1)
- Dental Anaesthesia
- Other Therapies
- By End User
- Pharmaceutical Companies
- Biotechnology Firms
- CMOs / CDMOs
- Other End-users (animal health, dental clinics)
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 38.21% pharmaceutical cartridge market share in 2025 backed by heavy capital projects such as Novo Nordisk’s USD 4.1 billion fill-finish campus and SCHOTT Pharma’s USD 371 million polymer syringe plant in North Carolina. FDA encouragement of advanced manufacturing accelerates AI and modular isolator uptake, positioning the region as a global benchmark for next-gen production.Europe follows closely owing to Annex 1 sterility reforms that push RTU adoption. Stevanato Group’s new Cisterna di Latina facility adds regional capacity for EZ-fill cartridges, aligning with the EU Critical Medicines Act that seeks supply-security via local output. Joint clinical-assessment rules and the forthcoming Health Technology Assessment Regulation unify demand, favouring suppliers with proven conformity across multiple markets.
Asia Pacific is forecast to grow 9.84% CAGR through 2031, the fastest worldwide. India’s Kapoor Glass exports 90% of its cartridge output to Western clients, underpinning the region’s cost-efficient manufacturing base. Regulatory harmonization through the Asia Partnership Conference of Pharmaceutical Associations sparks smoother cross-border approvals. Countries like South Korea and Singapore nurture biotech hubs, while China’s expanding biologics sector heightens need for high-quality containment. Collectively these initiatives cement Asia Pacific as a pivotal growth engine for the pharmaceutical cartridge market.
List of Companies Covered in this Report:
- Stevanato Group
- SCHOTT
- West Pharmaceutical Services
- Gerresheimer
- Nipro
- Datwyler Holding
- AptarGroup
- Merck KGaA (Sigma Aldrich cartridges)
- Transcoject GmbH
- Shandong Medicinal Glass
- Terumo
- Becton Dickinson & Co.
- Ypsomed
- Haselmeier GmbH (medmix)
- Vetter Pharma International
- Owen Mumford
- Cole Parmer (Glass Cartridges)
- Baxter
- CordenPharma Integra Plastics
- SGD Pharma
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size and Growth Forecasts (Value-USD)
6 Competitive Landscape
7 Market Opportunities and Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Stevanato Group
- Schott AG
- West Pharmaceutical Services
- Gerresheimer AG
- Nipro Corporation
- Datwyler Holding
- AptarGroup
- Merck KGaA (Sigma Aldrich cartridges)
- Transcoject GmbH
- Shandong Medicinal Glass
- Terumo Corporation
- Becton Dickinson & Co.
- Ypsomed AG
- Haselmeier GmbH (medmix)
- Vetter Pharma International
- Owen Mumford Ltd.
- Cole Parmer (Glass Cartridges)
- Baxter International Inc.
- CordenPharma Integra Plastics
- SGD Pharma
